(NASDAQ: VKTX) Viking Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Viking Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VKTX's revenue for 2025 to be $2,825,908,600, with the lowest VKTX revenue forecast at $2,825,908,600, and the highest VKTX revenue forecast at $2,825,908,600. On average, 1 Wall Street analysts forecast VKTX's revenue for 2026 to be $1,130,363,440, with the lowest VKTX revenue forecast at $1,130,363,440, and the highest VKTX revenue forecast at $1,130,363,440.
In 2027, VKTX is forecast to generate $335,717,942 in revenue, with the lowest revenue forecast at $335,717,942 and the highest revenue forecast at $335,717,942.